



Granzyme M and K release in human experimental endotoxemia



Annette C. Wensink^{a,b}, Maryse A. Wiewel^c, Lieneke H. Jongeneel^{b,d}, Marianne Boes^{b,d}, Tom van der Poll^c, C. Erik Hack^b, Niels Bovenschen^{a,b,*}

^a Department of Pathology, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands

^b Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands

^c Center for Experimental and Molecular Medicine, Amsterdam Medical Center, University of Amsterdam, Amsterdam 1100 DD, The Netherlands

^d Department of Pediatrics, University Medical Center Utrecht, Utrecht 3584CX, The Netherlands

ARTICLE INFO

Article history:

Received 23 November 2015

Received in revised form 16 February 2016

Accepted 16 February 2016

Available online 24 February 2016

Keywords:

Granzyme K

Granzyme M

Lipopolysaccharide (LPS)

Inflammation

Endotoxemia

ABSTRACT

Granzymes are serine proteases involved in killing of tumor cells and virally infected cells. However, granzymes are also upregulated in blood under inflammatory conditions and contribute to cytokine release and processing. Here, we show that granzyme M (GrM) and to a lesser extent GrK are transiently elevated in the circulation following LPS administration in humans. GrM is released upon stimulation of whole blood with LPS or the gram-negative bacteria *Escherichia coli* BL21, *Pseudomonas aeruginosa*, and *Neisseria meningitidis*. GrK is only released upon stimulation with *P. aeruginosa*. Thus, GrM and GrK are differentially released in response to LPS and gram-negative bacteria.

© 2016 Elsevier GmbH. All rights reserved.

1. Introduction

Severe sepsis is a major health problem, resulting in a significant number of deaths each year (Angus and van der Poll, 2013). The disease is caused by a local microbial infection that spreads to the circulation, resulting in a systemic inflammatory disorder that can cause irreversible organ injury and may ultimately result in death (Angus and van der Poll, 2013). Although mortality rates of sepsis have dropped over the past decades due to improved hospital care of patients, 20–30% of patients with severe sepsis still die, and effective treatment options are lacking (Angus and van der Poll, 2013).

Granzymes are a set of homologous serine proteases expressed in cytotoxic lymphocytes and are involved in the killing of tumor cells and virally infected cells (Bovenschen and Kummer, 2010). In humans, there are five granzymes: granzyme A (GrA), GrB, GrH, GrK, and GrM. Following target cell recognition by cytotoxic lymphocytes, granzymes are directed inside the target cell where they can activate pro-apoptotic pathways by cleavage of various sub-

strates, resulting in apoptosis (Bovenschen and Kummer, 2010; Chowdhury and Lieberman, 2008).

In addition to their cytotoxic potential, granzymes also play a role in inflammation. Levels of soluble granzymes A, B, K, and M are elevated in the circulation under inflammatory conditions, including endotoxemia and sepsis (Wensink et al., 2014; Lauw et al., 2000; Zeerleder et al., 2005; Hollestelle et al., 2011; Rucevic et al., 2007; Buzza and Bird, 2006). GrM and GrA knockout mice survive longer than wild-type (WT) mice, in response to a normally lethal LPS challenge (Anthony et al., 2010; Metkar et al., 2008), and GrM^{-/-} mice express lower levels of cytokines than WT mice upon LPS challenge (Anthony et al., 2010). In addition, we have recently demonstrated that GrK synergistically potentiates cytokine responses from human monocytes induced by LPS or gram-negative bacteria (Wensink et al., 2014). This suggests that granzymes are involved in the (innate) immune response against bacterial infections.

Soluble GrA and GrB are released in serum during experimental human endotoxemia and following stimulation of whole blood with LPS and bacteria (Lauw et al., 2000). However, it remains unknown whether GrK and GrM are also secreted in response to stimulation with LPS or bacteria. Here, we report that injection of LPS into healthy volunteers triggers a temporary increase in soluble GrM and, to a lesser extent, GrK levels. Whole blood stimulation with LPS or three strains of gram-negative bacteria results in GrM release, whereas GrK release is more restricted and is observed only

* Corresponding author at: Department of Pathology, University Medical Center Utrecht Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Fax: +31 30 2544990.

E-mail address: n.bovenschen@umcutrecht.nl (N. Bovenschen).

upon stimulation with the gram-negative bacterium *Pseudomonas aeruginosa*, but not with *Escherichia coli* BL21, *Neisseria meningitidis*, or LPS.

2. Materials and methods

2.1. Experimental human endotoxemia

Five healthy nonsmoking male volunteers (mean age: 24.4 years, range: 21–30 years) were admitted to the Clinical Research Unit of the Academic Medical Center, Amsterdam. Physical and routine laboratory examination were normal, as well as medical history and electrocardiography. Each volunteer was given a bolus intravenous (i.v.) injection of 4 ng/kg LPS (*E. coli* O113, CC-RE lot 3, National Institutes of Health, USA), administered over 1 min in an antecubital vein. Blood was collected in EDTA tubes immediately before injection, and furthermore at time points 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 20 h post injection. After centrifugation, plasma was transferred to clean vials and stored at -80°C until analysis. The clinical response of the volunteers to the LPS injection, as well as their leukocyte and lymphocyte counts, were similar to previously published results (Lauw et al., 2000). The study was approved of by the Medical Ethics Commission of the AMC, Amsterdam, The Netherlands, and written informed consent was obtained from all subjects.

2.2. Whole blood stimulation with LPS or gram-negative bacteria

Whole blood from healthy volunteers (other than described in the previous paragraph) was collected in sodium heparin Vacutainers (Becton Dickinson). Blood was diluted in serum-free RPMI 1640 to a final dilution of 1:5 (blood:RPMI). LPS (*E. coli* 0111:B4) (0–50 ng/ml) was added and samples were incubated for 0–24 h under standard incubator conditions (37°C , 5% CO_2 , relative humidity (RH) 95%). After incubation, blood was collected and centrifuged at 4°C for 5 min at 500 g. Plasma supernatants were transferred to clean eppendorf tubes and stored at -20°C until analysis. Alternatively, whole blood was stimulated with live gram-negative bacteria added in a 2-fold excess compared to PBMC numbers ($\sim 1 \times 10^6$ PBMCs/ml in whole undiluted blood). *Escherichia coli* BL21 (*E. coli* BL21), *P. aeruginosa* 01 (PA-01), or *Neisseria meningitidis* HB-1 (NM) were used. All bacterial strains were a kind gift from the Medical Microbiology Department (UMC, Utrecht). Bacteria were grown overnight on TSASB plates at 37°C , except for *N. meningitidis*, which was grown on GB-Choco plates (37°C , 5% CO_2 , RH 95%). Bacteria were diluted in PBS to OD ~ 0.5 at 660 nm (representing approximately 5×10^8 bacteria/ml), and added in the correct concentration to whole blood pre-diluted as described above. After incubation, plasma samples were obtained as described above.

2.3. Granzyme and cytokine measurements in plasma and serum samples

GrM and GrK levels in samples were determined using ELISA (Uscn Life Science Inc., lower detection limit for both assays ~ 3 pg/ml). The specificity of the ELISAs was confirmed using Western Blot for GrM and GrK (data not shown). TNF α and IL6 were measured in EDTA anticoagulated plasma by Luminex multiplex assay using BioPlex 200 (BioRad, Hercules, CA).

2.4. Granzyme M FACS staining

PBMCs were isolated from healthy volunteers using Ficoll density gradient. Cells were cultured in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$

streptomycin. Cells (5×10^5) were treated with or without 20 ng/ml LPS for 18 h. Cells were incubated with one of two cell-surface marker combinations prior to determine GrM protein levels in different cell subsets: (1) CD3-Pacific Blue (Biolegend), CD8-PerCP, CD56-PE-Cy7, CD14-V500 (BD), CD16-APC (eBioscience); (2) CD3-Pacific Blue, CD4-PE-Cy7 (Biolegend), CD8-PerCP (BD). Cells were subsequently permeabilized for intracellular GrM staining. After fixation and permeabilization, cells were incubated with Alexa Fluor 488-conjugated anti-GrM (clone 4B2G4) as we described previously (Bovenschen et al., 2014; de Koning et al., 2010). Samples were measured at FACS Canto II and analyzed using FACSdiva software. The monocytes were identified based on characteristic properties of the cells in the forward (FSC) and side scatter (SSC) and then divided in CD14+ and CD16+ monocytes. Within the lymphocyte gate based on FSC/SSC, the T cells were gated on CD3+ and then divided in CD4+ or CD8+. NK cells were gated as CD3-CD16+CD56+. NKT cells are gated as CD3+CD56+. Within these populations, the percentage of GrM+ cells was defined.

3. Results

3.1. GrM and GrK are released in human experimental endotoxemia

Human endotoxemia was modeled by injecting five healthy volunteers with LPS intravenously. Serum was collected at different time points post LPS injection, and granzymes were measured. Both GrK and GrM serum levels showed a temporary rise upon LPS injection (Fig. 1a and b). A major peak in GrM levels was observed after ~ 2 h, with a minor peak following after ~ 5 –8 h (Fig. 1a). A less clear but recognizable rise in GrK levels was observed in several donors (Fig. 1b). When GrK and GrM levels in individual volunteers are compared, peaks in GrK and GrM levels largely coincided (Fig. 1c–g). As expected, TNF α (Fig. 1h) and IL6 (Fig. 1i) levels in serum transiently increase following LPS injection, with peak levels that coincide with the peak levels of serum granzymes. However, there is no correlation between the absolute responses of granzymes and proinflammatory cytokines to LPS (at least in these 5 patients), suggesting that the different granzyme responses among individuals cannot be explained by different responses to LPS. These data indicate that GrM and to a lesser extent GrK are released in human experimental endotoxemia.

3.2. GrM, but not GrK, is released in LPS-treated whole blood cultures

We next addressed whether LPS can trigger GrK and GrM release in whole blood. Incubation of whole blood with LPS induced a clear time-dependent increase in soluble GrM levels (Fig. 2a), observed in four out of five donors. In contrast, no GrK release was observed under the same circumstances in four out of five donors tested (Fig. 2b). In one donor, minor amounts of GrK were released (~ 30 pg/ml after 24 h incubation with 50 ng/ml LPS). No granzyme was detected without incubation or after incubation of untreated blood (Fig. 2a and b). Subsequently, we measured intracellular GrM expression in several PBMC subsets of four independent donors upon LPS treatment. The amount of GrM-positive cells did not change in NK cell, NKT cell, CD8+ T cell, CD4+ T cell, and CD14+ monocyte subsets (Fig. 2c). Surprisingly, however, CD16+ monocytes did express GrM (unstimulated), and this GrM expression increased following LPS treatment (in three out of four donors). Taken together, these data indicate that GrM, but not GrK, is released in response to LPS stimulation.

Download English Version:

<https://daneshyari.com/en/article/2182725>

Download Persian Version:

<https://daneshyari.com/article/2182725>

[Daneshyari.com](https://daneshyari.com)